167 related articles for article (PubMed ID: 8159916)
1. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure.
Davenport A; Goel S; Mackenzie JC
Scand J Urol Nephrol; 1993; 27(4):447-51. PubMed ID: 8159916
[TBL] [Abstract][Full Text] [Related]
2. Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient.
Trimarchi H; Lombi F; Forrester M; Elizondo C; Sawinski D; Pereyra H; Freixas E
Nat Clin Pract Nephrol; 2006 Aug; 2(8):459-63; quiz 464. PubMed ID: 16932480
[TBL] [Abstract][Full Text] [Related]
3. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
4. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
[TBL] [Abstract][Full Text] [Related]
5. Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis.
Saif I; Halim A; Altaf A; Saif M; Khalid M; Ahmad D; Imran H
J Ayub Med Coll Abbottabad; 2007; 19(4):26-8. PubMed ID: 18693591
[TBL] [Abstract][Full Text] [Related]
6. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Jansson S; Tisell LE; Lindstedt G; Lundberg PA
Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
[TBL] [Abstract][Full Text] [Related]
7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
8. Administration of pamidronate helps prevent immediate postparathyroidectomy hungry bone syndrome.
Davenport A; Stearns MP
Nephrology (Carlton); 2007 Aug; 12(4):386-90. PubMed ID: 17635755
[TBL] [Abstract][Full Text] [Related]
9. CAPD with low calcium dialysate and calcium carbonate: results of a 24-week study.
Honkanen E; Kala AR; Grönhagen-Riska C; Ikäheimo R
Adv Perit Dial; 1992; 8():356-61. PubMed ID: 1361822
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of calcium carbonate in children with chronic renal failure.
Clark AG; Oner A; Ward G; Turner C; Rigden SP; Haycock GB; Chantler C
Nephrol Dial Transplant; 1989; 4(6):539-44. PubMed ID: 2507975
[TBL] [Abstract][Full Text] [Related]
11. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
12. Milk-alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients.
Picolos MK; Lavis VR; Orlander PR
Clin Endocrinol (Oxf); 2005 Nov; 63(5):566-76. PubMed ID: 16268810
[TBL] [Abstract][Full Text] [Related]
13. Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient.
Czosnowski LM; Hudson JQ; Canada RB
Am J Med Sci; 2009 Apr; 337(4):300-1. PubMed ID: 19365180
[TBL] [Abstract][Full Text] [Related]
14. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.
Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT
Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202
[TBL] [Abstract][Full Text] [Related]
15. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
16. Audit of the use of calcium carbonate as a phosphate binder in 100 patients treated with continuous ambulatory peritoneal dialysis.
Davenport A; Goel S; MacKenzie JC
Nephrol Dial Transplant; 1992; 7(7):632-5. PubMed ID: 1323075
[TBL] [Abstract][Full Text] [Related]
17. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
18. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
Walls J; Ratcliffe WA; Howell A; Bundred NJ
Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
[TBL] [Abstract][Full Text] [Related]
19. The use of pamidronate in three children with renal disease.
Sellers E; Sharma A; Rodd C
Pediatr Nephrol; 1998 Nov; 12(9):778-81. PubMed ID: 9874327
[TBL] [Abstract][Full Text] [Related]
20. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
